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Background: Betaine is a methyl donor and has been considered as a lipotropic effect substance. But its
mechanism remains unclear. Hepatic steatosis is associated with abnormal expression of genes involved in hepatic
lipid metabolism. DNA methylation contributes to the disregulation of gene expression. Here we hypothesized that
betaine supplement and subsequent DNA methylation modifications alter the expression of genes that are involved
in hepatic lipid metabolism and hence alleviate hepatic triglyceride accumulation.
Methods: Male wild-type (WT) C57BL/6 mice (n = 6) were fed with the AIN-93 G diet. ApoE−/− mice (n = 12),
weight-matched with the WT mice, were divided into two groups (n = 6 per group), and fed with the AIN-93 G diet
and AIN-93 G supplemented with 2% betaine/100 g diet. Seven weeks after the intervention, mice were sacrificed.
Liver betaine, choline, homocysteine concentration were measured by HPLC. Liver oxidants activity and triglyceride
level were assessed by ultraviolet spectrophotometry. Finally, hepatic PPAR alpha gene and its target genes
expression levels and the methylation status of the PPAR alpha gene were determined.
Results: ApoE−/− mice had higher hepatic triglyceride and lower GSH-Px activity when compared with the WT
mice. Betaine intervention reversed triglyceride deposit, enhanced SOD and GSH-Px activity in the liver.
Interestingly, mice fed on betaine-supplemented diet showed a dramatic increase of hepatic choline concentration
and a decrease of betaine and homocysteine concentration relative to the WT mice and the ApoE−/− mice absent
with betaine intervention. Expression of PPAR alpha and CPT1 were decreased and expression of FAS was markedly
increased in ApoE−/− mice. In parallel, PPAR alpha promoter methylation level were slightly increased in ApoE−/−
mice though without significance. Betaine supplement upregulated expression of PPAR alpha and its target genes
(CPT1, CYP2E1) and reversed hypermethylation of PPAR alpha promoter of ApoE−/− mice. Furthermore, PPAR alpha
methylation was positively correlated with hepatic betaine concentration.
Conclusions: Our findings indicate that betaine supplement could alleviate hepatic triglyceride accumulation and
improve antioxidant capacity by decreasing PPAR alpha promoter methylation and upregulating PPAR alpha and its
target genes mRNA expression.
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Figure 1 Effects of betaine supplement on body weight gain.
WT mice were fed with the AIN-93 G diet, while ApoE−/− mice were
fed with the AIN-93 G in the absence and presence of 2% betaine.
Values are means ± SE (n = 6). These data were tested by ANOVA.
*P < 0.05 vs WT group.
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Triglyceride (TG) accumulation in hepatocytes is consid-
ered the primary manifestation of fatty liver disease [1].
In addition, the increase of liver triglyceride deposit is
associated with obesity, hepatocellular carcinoma [2] and
atherosclerosis [3]. Therefore, relieving hepatic lipid accu-
mulation is viewed as potentially promising strategy for the
prevention of many chronic diseases. The pathogenesis of
hepatic TG deposit is incompletely understood. A previous
study by others has shown that upregulation of genes
expression for de novo lipogenesis (FAS, fatty acid synthase;
ACC, acetyl-CoA carboxylase) and downregulation of
genes expression for fatty acid oxidation (PPARα,
peroxisomal proliferator-activated receptor alpha; CPT1,
carnitine palmitoyl transferase I; UCP2, uncoupling
proteins; ACOX, acyl-CoA oxidase; CYP2E1, cyto-chrome
P450 2E1) are involved in the onsets of triglyceride
accumulation in the liver [4].
Betaine, a methyl donor, is a naturally occurring com-
pound in common foods, such as wheat bran, wheat germ,
spinach, pretzels, shrimp and wheat bread etc. [5]. In vivo,
betaine can also be produced by oxidation of choline, and it
serves as an effective methyl donor for remethylating
homocysteine (Hcy) into methionine (Met). DNA methy-
lation in the CpG islands is one of the epigenetic mecha-
nisms to regulate gene expression. Choline and methionine
deficiency in diet are closely associated with biological func-
tions by differentially methylated and inversely expressed
genes in the tissue [6-8]. Mice with hyperhomocysteinemia,
induced by heterozygous cystathionine β-synthase
deficiency, show diminished methylation capacity and
hypermethylation silencing of Fads2 mRNA expres-
sion which contribute to the impaired transport of
TG [9]. High-fat diet can exacerbate methyl donors defi-
ciency [10] and strikingly produce high level of serum Hcy,
which may promote hypermethylation of MTTP gene and
down-regulation of its expression, resulting in the hin-
drance to assembly lipoprotein and export lipid from liver
[11]. It has become clear that PPARα can regulate the tran-
scription of a suite of genes encoding enzymes in hepatic
mitochondrial (CPT1, UCP2) and extramitochondrial
(ACOX, CYP2E) fatty acid oxidation. Mice deficient in
PPARα is demonstrated as a useful mouse model of fatty
liver because of its important role in fatty acid oxidation
and alleviation of hepatic TG [12]. Although An accumulat-
ing clinical and experimental evidences suggest that betaine
is a lipotropic substance [13-15], the DNA methylation
mechanism remains to be clearly defined.
In the present study, We attempt to investigate
betaine supplement undergoing improvement on lipid
metabolism and antioxidant capacity through changes
in methylation level of PPARα promoter and expres-
sion of PPARα and its target genes(CPT1, UCP2,
ACOX, CYP2E) in ApoE−/− mice .Results
Effect of betaine supplement on body weight and
liver weight
Body weight was matched before grouping. Absolute body
weight of each mouse from each group was measured
weekly and summarized in Figure 1. As anticipated, body
weight was increased after experiment initiation, gaining
most rapidly in WT mice. No significant difference of
body weight gain was found among groups, although the
body weight gain in betaine-supplemented ApoE−/− mice
was significant lower than that in WT mice after 6 weeks.
Additionally, there were no significant differences in
liver weight (F = 2.422, P = 0.075) and liver/body
weight ratio (F = 0.533, P = 0.712) among the mice fed
with or without betaine at 7 weeks (data not shown).
These results suggested that betaine supplement had
no significant influence on either the liver weight or
the body weight.Betaine supplement alleviates hepatic TG accumulation
and improves antioxidant capacity
As anticipated, ApoE−/− mice fed with the AIN-93 G diet
showed significantly higher hepatic TG content than that
in the WT mice. After supplemented with betaine,
hepatic TG level was significantly reduced (F = 19.040,
P < 0.001) (Figure 2A). Hepatic GSH-Px activity in the
ApoE−/− mice was significantly lower than that in the
WT mice, while betaine supplement strikingly increased
GSH-Px activity (F = 9.696, P < 0.001) (Figure 2B). Con-
sistently, betaine feeding led to an significant elevation of
hepatic SOD activity (F = 8.865, P < 0.001) (Figure 2C).
We hence suggested that betaine intervention was able to
ameliorate hepatic TG deposit and improve antioxidant






































































Figure 2 Effects of betaine supplement on hepatic TG levels (A) and GSH-Px (B) and SOD (C) activity. WT mice were fed with the
AIN-93 G diet, while ApoE−/− mice were fed with the AIN-93 G in the absence and presence of 2% betaine. Values are means ± SE, n = 6. *P < 0.05
vs WT group, # P < 0.05 vs ApoE−/− group.
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and Hcy concentration
Hepatic betaine concentrations in the ApoE−/− mice
were markedly higher and hepatic Hcy were signifi-
cantly lower when compared with the WT mice. For
the ApoE−/− mice, betaine supplement normalized
hepatic betaine levels (F = 11.014, P < 0.001) (Figure 3A),




















































Figure 3 Effects of betaine supplement on liver betaine (A), choline (B
ApoE−/− mice were fed with the AIN-93 G in the absence and presence of
# P < 0.05 vs ApoE−/− group.P < 0.001) and reduced Hcy levels (F = 11.516, P < 0.001)
(Figure 3B and 3C).
The effect of betaine supplement on the expression of
lipid metabolism related genes
In the ApoE−/− mice, hepatic PPARα and CPT1 expres-
sion levels showed a trend of reduction when compared























) and Hcy (C) levels. WT mice were fed with the AIN-93 G diet, while





















Figure 5 Detection of aberrant promoter methylation of the
PPARa gene by real-time quantitative MSP. WT mice were fed
with the AIN-93 G diet, while ApoE−/− mice were fed with the AIN-93
G in the absence and presence of 2% betaine.
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PPARα (3.93 folds) and CYP2E1 (1.82 folds), however,
was detected in the ApoE−/− mice by betaine supple-
mentation (F = 12.494, P < 0.001) (Figure 4). Mean-
while, hepatic FAS mRNA levels in the ApoE−/− mice
were significantly higher than the WT controls, while
betaine treatment significantly attenuated its expres-
sion levels. Despite these changes, betaine supplement
did not exert effect on expression of other lipogenic
and oxidative genes, such as ACC, UCP2, ACOX.
These data suggested that betaine supplement select-
ively altered expression of certain genes. These results
prompted us to further examine whether gene expres-
sion change in response to betaine supplement was
influenced by DNA methylation.
Betaine supplement decreases methylation level of
hepatic PPARa promoter
We then chose the PPARα as target gene and utilized a
real-time quantitative MSP method to quantitatively
assess the methylation levels of PPARα promoter region
in the liver. The average methylation in the PPARα
gene promoter region of the ApoE−/− mice was
4.64%,compared with 2.58% in the WT mice.Betaine
supplementation showed a trend of decreasing the
methylation level, although the difference didn’t
reach a statistical difference level (Figure 5). Reduced
methylation levels of PPARα promoter was accom-
panied by increased expression of the PPARα gene.
A positive relationship was also found between the
hepatic betaine levels and the methylation levels of
the PPARα promoter (β = 0.572, P = 0.005) (Figure 6).
These results collectively suggested that the DNA
methylation at the PPARα gene promoter could be
























Figure 4 Effect of betaine supplement on the expression of selected
AIN-93 G diet, while ApoE−/− mice were fed with the AIN-93 G in the absen
*P < 0.05 vs WT group, # P < 0.05 vs ApoE−/− group.Discussion
The current study was designed to determine whether beta-
ine intervention improves hepatic TG metabolism and anti-
oxidant capacity in the ApoE−/− mice. There are two novel
findings of this study. The first one is that betaine supple-
ment can reduce hepatic TG content and improve antioxi-
dant capacity,associated with the normalization of the
expression of PPARα, CYP2E1,CPT1 and FAS. Secondly,we
show here a tendency of increased DNA methylation in the
PPARα promoter in the ApoE−/− mouse liver while betaine
supplement is able to reverse the hypermethylation of the
PPARα promoter.
ApoE−/− mouse is the classical modle of AS and
dyslipidemia, characterized by high levels of plasma choles-
terol and/or TG or low level of HDL, in addition, this
mouse model indicates some incline to express fatty liver
[16]. Our previous study [17] has shown that betaine has
an anti-atherosclerosis effect in the ApoE−/− mice. We fur-
ther evidenced that betaine intervention effectively relieved










key genes involved in lipid metabolism. WT mice were fed with the




























Figure 6 Linear correlation analysis of DNA methylation level of PPARα promoter vs the hepatic betaine levels. WT mice were fed with
the AIN-93 G diet, while ApoE−/− mice were fed with the AIN-93 G in the absence and presence of 2% betaine.
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have been proved to influence genes expression involved in
the process of lipid metabolism [4,8,9,11,18]. Fatty acids in
the liver are derived from the de novo lipogenesis and the
uptake from plasma, and catabolized by oxidation or
exportation in the form of VLDL-TG. Fatty acid oxidation
occurs mainly in the mitochondria, in which ATP is gener-
ated simultaneously. When the impairment of antioxidant
capacity in mitochondria generated by excessive fatty acid
occurs, the alternative peroxisomal β-oxidation and micro-
somal ω-oxidation will be activated which inevitably lead
to the production of reactive oxygen species (ROS), includ-
ing hydrogen peroxide (H2O2) and superoxide. PPARα is
highly expressed in the liver and it is well-known to
promote fatty catabolism by up-regulation of genes in
mitochondral and extramitochondral fatty acid oxidation.
The expression of hepatic PPARα expression has shown
to be down-regulated in NAFLD patients [4], ApoE−/−
mice also exhibited reduced hepatic PPARα expression
compared with WT mice though without statistical
significance in our present study. As we have expected,
betaine supplement in ApoE−/− mice dramatically upre-
gulated PPARα gene expression. The expression of CPT1, a
key rate-limiting enzyme in mitochondral oxidation, just
mirrored the alteration of PPARα expression in response to
betaine treatment. CYP2E1 is one of the targets of PPARα,
a key enzyme in the microsomal ω-oxidation. CYP2E1
overexpression in the liver is a definite factor for oxidative
stress [19]. In the current study, we found that betaine
treatment increased CYP2E1 expression which was
paralleled by increased PPARα expression. We hence
further investigated the activity of SOD and GSH-Px since
these two enzymes are involved in the elimination of ROS
derived from fatty acid oxidation. We observed adiminished antioxidant capacity in ApoE−/− mice, but ele-
vated antioxidant activity in the liver of the ApoE−/− mice
fed with betaine. These results indicated that CYP2E1
overexpression is unable to induce oxidative stress,
but how ApoE−/− mice showed elevated hepatic TG
and diminished antioxidant capacity and how betaine
supplement reversed it? FAS and ACC are two key
enzymes in the process of fatty acid synthesis. The
current results revealed that expression of FAS was
increased by five folds in the liver of the ApoE−/−
mice when compared with WT controls, while betaine
treatment strikingly repressed it. Accumulation of excessive
hepatic TG and consequent oxidative stress have been con-
firmed to be the two common “hits” in the development of
NAFLD [1]. Betaine treatment significantly increased
PPARα, CPT1 and CYP2E1 expression and reduced the
expression of FAS, the latter effect impaires fatty acid
synthesis so as not to supply substrate for lipid peroxida-
tion, and enhanced mitochondrial oxidation is sufficiently
powerful to prevent TG deposit and oxidative stress.
The precise mechanisms by which betaine up regulates
gene expression remain largely unclear. DNA methylation
is one of the epigenetic modifications involved in the regu-
lation of gene expression and hence versatile biological
functions. Significant loss of global methylation was
observed in the ApoE−/− mice by other investigators [20]. It
is widely accepted that cells could undergo global DNA
hypomethylation but simultaneously possess hyperme-
thylation of a specific gene promoter, while the expression
of a gene is usually silenced or attenuated when its pro-
moter is heavily methylated. Methyl-deficient diet has been
evidenced to exhibit hypermethylation promoter of genes
involved in lipid metabolism which has inverse relationship
with gene expression [8]. Betaine with its three chemically
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DNA, RNA, histone and proteins, and its supplement may
reverse alterations in DNA methylation induced by methyl
deficiency. Here we investigated for the first time whether
PPARα promoter methylation and corresponding gene
expression can be affected by betaine supplement.
The results of quantitative MSP assay showed that
the methylation level of PPARα promoter was higher
in the ApoE−/− mice when compared with that of WT
mice, while betaine treatment showed a tendency to
attenuate it. In attempt to explore the underlying
mechanism, we did further analysis and found out
that PPARα promoter methylation level was positively
correlated with hepatic betaine concentration.
In present study, betaine supplement significantly
decreased Hcy concentration and increased hepatic choline
concentration. Unexpectedly, betaine treatment decreased
hepatic betaine concentration as well. Endogenous betaine
is oxidized from choline by two steps. Choline dehydrogen-
ase (CHDH) mediates the first committed step for the for-
mation of betaine aldehyde from choline, which is further
catalyzed into betaine by betaine aldehyde dehydrogenase
(BADH). Once betaine is formed, it serves as methyl donor
for remethylating Hcy into Met by betaine-homocysteine
methyltransferase (BHMT). Hepatic CHDH is rarely
affected by dietary methionine and choline [21], but it has
been shown to be competitively inhibited by both betaine
aldehyde and betaine [22]. BHMT is expressed primarily in
the liver of humans and mice [23]. Betaine-alone supple-
mentation results in a 2-fold elevation of hepatic BHMT
levels and activities [24]. Thus, betaine-elicited repression
of CHDH as well as of activation BHMT can collectively
increase the catabolism but decrease the synthesis of beta-
ine in the liver. Our finding that betaine treatment
dramaticly increased choline level and reduced Hcy level in
the liver also confirmed this effect. This is among potential
explainations why liver betaine levels in the betaine-
supplemented ApoE−/− mice dropped to the levels that
were comparable with the levels in the WT mice. We
hence suggest that hepatic betaine depletion plays a role in
the hypomethylation of PPARα promoter.
On the other hand, choline, another methyl donor,
was observed to dramaticly increase by betaine intake.
Betaine has been proved to have choline-sparing effect
[25]. Choline is a basic component for the synthesis of
Phosphatidylcholine (PC) which takes part in the assembly
of mature VLDL. Betaine-containing diet could enhance
the synthesis of hepatic SAM as well as the activity of phos-
phatidylethanolamine methyltransferase (PEMT), which
subsequently facilitates the metabolic conversion of phos-
phatidylethanolamine (PE) to form PC [24]. ApoE−/− mice
is characterized by lipid accumulation and the development
of hepatic steatosis. As a result, more choline are available
to increase PC synthesis and PC:PE ratio in VLDL, therebypromoting VLDL secretion and lipid transport [26]. These
results suggest that betaine supplement exert important
effects on the pool of related metabolites in the liver,
whereby reduced betaine concentration in the liver connot
supply enough substrate for DNA methylated modification
and may selectively decrease the methylation statue of
certain gene involved in lipid metabolism.Conclusion
Taken together, the present study reports for the first time
that betaine intervention reduces hepatic TG content and
improves antioxidant capacity in the ApoE−/− mouse model.
This is partially achieved by upregulating PPARα gene
expression, as a result of hypomethylation of its promoter.
These findings provided a novel insight into the important
lipotropic effect of betaine. Due to its fundamental impor-
tant role as a methyl-donor, betaine is gradually become a
new target for the intervention of many chronic metabolic
diseases. The hepatic and vascular protective effects of
betaine we found provide promising insight into the human
nutrition. Our present study has also build up a strong
basis for further evaluation of potential mechanisms of
betaine in epigenetic studies.Methods
Chemicals
Choline chloride, Betaine glycine, d9-Betaine (internal
standard), d9-choline (internal standard), trichloroacetic
acid (TCA), tris (2-carboxylethyl) phosphine (TCEP),
ammonium-7- fluorobenzo-2-oxa-1, 3-diazole-4-sulfonic
acid (SBD-F), mercaptopropionylglycine (MPG), mineral
oil were purchased from Sigma Chemicals. Methanol,
chloroform, acetonitrile, formic acid were HPLC grade
and obtained from Merck Chemical.Animals and diet
Male wild-type (WT) C57BL/6 mice (n = 6) and ApoE−/−
mice on the C57BL/6 background (n = 12) were obtained
from the Jackson Laboratories (Bar Harbor, ME, USA).
All mice were acclimated on a standard AIN-93 G diet
for one week. The ApoE−/− mice were weight-matched
and divided into two groups (n = 6 per group) feeding
with the AIN-93 G diets supplemented with 0, 2 g
betaine/100 g diet and the WT mice continue to
consume the AIN-93 G diet. All mice were housed at a
constant temperature, humidity and 12 hR light/dark
cycle, and freely accessed to food and water for 7 weeks.
Body weight and consumption of diet were recorded
weekly. Mice were anesthetized and sacrificed after the
experiment, liver were excised and stored at −80°C. This
study was approved by the Institutional Animal Care
and Use Committee at Sun Yat-Sen University.
Table 1 Oligo-nucleotide primer pairs for detecting of







PPARa M F: TTTTTACGAATTTTCGGGATTC 55 164
R: AAAAAATACGCCTTAACGCG
PPARa U F: TTTTTTTATGAATTTTTGGGATTTG 55 169
R: TAAAAAAAATACACCTTAACACACA
PPARa F: GGGCAAGAGAATCCACGAAG 60 91
R: GTTGTTGCTGGTCTTTCCCG
CYP2E1 F: TGCAGTCCGAGACAGGATGA 60 82
R: GGAAGGGACGAGGTTGATGA
CPT1 F: AGCACACCAGGCAGTAGCTT 60 144
R: AGGATGCCATTCTTGATTCG
UCP2 F: TCTCCTGAAAGCCAACCTCAT 60 272
R: GCTGCTCATAGGTGACAAACAT
ACOX F: AGGTTCAGTCGGGGAAGCTGG 60 433
R: ATCTGAGCCCCTGTGATGATG
FAS F: GCTGCGGAAACTTCAGGAAAT 60 84
R: AGAGACGTGTCACTCCTGGACTT
ACC F: CACTGTGAACATGTGGAGG 60 155
R: AGGCTGATGGTGATGACC
β-Actin F: GGGTCAGAAGGACTCCTATG 60 90
R: GTAACAATGCCATGTTCAAT
Sequences with bold font mean CpG site in the primers.
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the animal tissue
One hundred mg frozen liver tissue were homogenized in
600 μl methanol/chloroform (2:1,V/V) using an Ultrasonic
Cell Disruptor (PRO scientific Inc. USA). The mixture was
vortex-mixed vigorously and left at −20°C overnight. After
the extraction, the mixture was centrifuged at 1500 g for
5 min. The supernatants were drawn and transferred to
new tubes. The residuals were mixed with 300 μl metha-
nol/chloroform/water (2:1:0.8,V/V/V) and centrifuged at
1500 g for 5 min. The supernatants from the two extrac-
tions were pooled. One hundred μl chloroform and 100 μl
water were added into the mixture to form two phases.
After a centrifugation, the aqueous phase was taken by a
syringe, dried by N2 Blowing Concentrator (Organomation
Associates Inc, America) and dissolved in 20 μl water.
The dissolved water were treated with 800 μl methanol,
100 μl acetonitrile containing 10 μM internal standard
and centrifuged at 6000 g for 2 min to precipitate protein.
Finally the supernatants were injected into high perfor-
mance liquid chromatography-tandem mass spectrometry
(HPLC-MS) to analysis [27].
Determination of Hcy concentration in the animal tissue
Twenty five mg frozen liver tissue was homogenized in
200 μl cold PBS using an Ultrasonic Cell Disruptor (PRO
scientific Inc, USA). The homogenized tissue suspension
was treated with 50 μl TCEP (120 mg/ml) and 60 μl MPG
(10 μM), vortex-mixed thoroughly, and incubated at 37°C
for 30 min. After adding 125 μl TCA (100 g/L with 1 mM
EDTA) and vortex-mixing thoroughly, the precipitated
proteins were immediately centrifugated at 13000 g for
10 min. One hundred μl supernatant was incubated with
125 μl borate buffer (0.125 M, pH 9.5, with 4 mM EDTA),
10 μl NaOH solution (1.55 M) and 50 μl SBD-F solution
(1 g/L in borate buffer) at 60°C for 60 min, placed in the
room temperature to cool down, and then samples (10 μl)
were injected into HPLC system to analysis [28].
Bisulfite conversion of DNA
Genomic DNA was isolated from the liver tissue with the
TIANamp Genomic DNA Kit (TIANGEN, Beijing, China).
Treatment of DNA with bisulfite would result in the con-
version of unmethylated cytosines to uracils, while methyl-
ated cytosines would remain unaltered. Briefly, 5.5 μL of
3 M NaOH was added into 1 ~ 2 μg of DNA (50 μL vol-
ume) and incubated at 42°C for 20 min. Following the incu-
bation step, 520 μL of 3.6 M NaHSO3 (pH 5.0) and 30 μL
10 mM hydroquinone were added to each sample (fresh
and avoiding exposure to light). All reagents were softly
mixed, centrifuged and covered by mineral oil, then incu-
bated at 53°C for 16 h. The bisulfite-converted DNA was
purified by Wizard DNA Clean-Up System (Promega,
USA). Finally DNA was eluated with 54 μL DDW at 80°C.6 μL of 3 M NaOH was added into each sample and incu-
bated at 42°C for 15 min. Following the incubation, DNA
was precipitated using 6 μl of 3 M sodium acetate and
30 μl 100% cold ethanol at −80°C for 3 h. Each sample was
centrifuged 30 min at 12,000 g and the supernatant liquid
was poured out. The bisulfite-converted DNA was washed
by 70% ethanol, dried and finally resuspended in a total vol-
ume of 10 μl.
Real-time quantitative MSP
The chemically modified DNA was subsequently used as a
template for a QMSP method to determine the methylation
level of the selected CpG dinucleotides in the PPARα pro-
moter. For the methylation-specific PCR experiment, two
pairs of primers were designed to amplify either methylated
or unmethylated sequences: one pair was specific for
bisulfite-modified methylated DNA (M primers) and the
other pair was specific for bisulfite-modified unmethylated
DNA (U primers). The sequence was retrieved from NCBI
at http://www.ncbi.nlm.nih.gov/gene? with the accession
number [Genbank:NM_001113418.1]. Primers were
designed via methprimer on line (http://www.urogene.org/
methprimer/) and the sequences were shown in Table 1.
NIH 3 T3 mouse genomic DNA and fully methylated NIH
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were separately used as fully unmethylated and methylated
positive control. Negative water blanks were also included.
For each 20 μl Real-time quantitative PCR, 10 μl 2 × SYBRW
Premix Ex Taq TMII, 0.2 μl of 10 μM forward primer,
0.2 μl of 10 μM reverse primer, 0.4 μl of 50 × ROX, 2 μl
DNA template and 7.2 μl water were used. All of the re-
gents could be obtained from SYBRW Premix Ex Taq TM II
Kit(Takala). For the PPARa M and PPARa U Real-time
quantitative MSP, the condition was 94°C for 3 min
followed by 40 cycles of 94°C for 30 s, 55°C for 31 s, 72°C
for 30 s. Data acquisition at annealing phase were analysed.
After amplification, a melt curve was generated to confirm
the specificity of PCR product. Serial dilutions of fully
unmethylated amplified PCR product and fully methylated
amplified PCR product were used to establish calibration
curve. Data were collected by the Applied Biosystems 7500
fast real-time PCR system and analysed using 7500 software
V2.0.1. The methylation index in a sample and the com-
pleteness of bisulfite conversion was estimated as previ-
ously described by Y. M. Dennis Lo [29]. Each sample was
tested in duplicate. The melt curves in the present study
confirmed stable and specific PCR products in both meth-
ylated (M) and unmethylated (U) systems. The linearity
correlation coefficient of the standard curve of M system
was 0.999, which demonstrated a large dynamic range and
accuracy of real-time quantitative PCR. Similar results were
obtained from U system as well.RNA isolation and RT-PCR
Total RNA was isolated from the liver tissue with the
TRIZOL reagent (Invitrogen, USA) according to the
manufacturer’s instruction. The concentration and qual-
ity of total RNA was assessed by spectrophotometer, and
its integrity was tested on agarose gels. Two μg RNA
was reversely transcripted into cDNA with a commercial
kit (Invitrogen, USA). Quantitative analysis of gene
expression was performed by real-time polymerase
chain reaction with an Applied Biosystems 7500 fast
real-time PCR system. PCR primer information is
summarized in Table 1.Hepatic biochemical analysis
Total hepatic lipid was extracted by the method
presented by Folch and colleagues [30]. Hepatic TG con-
centrations were determined using commercially avail-
able kits (Biosino Bio-Technology and Science Inc,
Beijing, China) on a automatic biochemistry analyzer
(A25Biosystem, Spain). Hepatic Superoxide dismutase
(SOD), glutathione peroxidase (GSH-Px) activities
were determined using correspondent kits (Nanjing
Jiancheng Bio Inc, Nanjing, China) with ultraviolet
spectrophotometry.Statistic analysis
All results were presented as mean ± standard error (SE)
and tested by the analysis of one way ANOVA followed
by Bonferroni’s multiple comparison. Linear correlation
was conducted to assess the relationship between
hepatic betaine concentration and methylation level of
PPARα gene. A two-tailed P < 0.05 was considered
statistically significant.
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